PDF(Pubmed)
Abstract：
UNASSIGNED: Cardiovascular disease (CVD) poses a significant global health and economic challenge, with atherosclerosis being a primary cause. Over the past 40 years, substantial research has been conducted into the prevention and reversal of atherosclerosis, resulting in the development of lipid-lowering agents such as statins and fibrates. Despite the extensive literature and formulation of numerous therapeutic guidelines in this domain, a comprehensive bibliometric analysis of the current research landscape and trends has not been performed. This study aimed to elucidate the evolution and milestones of research into lipid-lowering treatments for coronary heart disease (CHD) in conjunction with hyperlipidemia through bibliometric analysis, offering insights into future directions for treatment strategies.
UNASSIGNED: This study examined publications from 1986 to 2023 retrieved from the Web of Science database (Core Collection). Utilizing tools such as VOSviewer, Pajek, and CiteSpace, we analyzed publication and citation numbers, H-indexes, contributions by countries and institutions, authorship, journal sources, and keyword usage to uncover research trajectories and areas of focus.
UNASSIGNED: Our analysis of 587 publications revealed a recent surge in research output, particularly post-2003. The American Journal of Cardiology published the highest number of studies, with 40 articles, whereas Circulation received the highest number of citations (6,266). Key contributors included the United States, Japan, and China, with the United States leading in citation numbers and the H-index. Harvard University and Leiden University emerged as pivotal institutions, and Professors J. Wouter Jukema and Robert P. Giugliano were identified as leading experts. Keyword analysis disclosed five thematic clusters, indicating a shift in research towards new drug combinations and strategies, signaling future research directions.
UNASSIGNED: The last 4 decades have seen a notable rise in publications on lipid-lowering therapies for CHD and hyperlipidemia, with the United States retaining world-leading status. The increase in international collaboration aids the shift towards research into innovative lipid-lowering agents and therapeutic approaches. PCSK9 inhibitors and innovative combination therapies, including antisense oligonucleotides and angiopoietin-like protein 3 inhibitors, provide avenues for future research, intending to maximize the safety and efficacy of treatment approaches.
UNASSIGNED: This study examined publications from 1986 to 2023 retrieved from the Web of Science database (Core Collection). Utilizing tools such as VOSviewer, Pajek, and CiteSpace, we analyzed publication and citation numbers, H-indexes, contributions by countries and institutions, authorship, journal sources, and keyword usage to uncover research trajectories and areas of focus.
UNASSIGNED: Our analysis of 587 publications revealed a recent surge in research output, particularly post-2003. The American Journal of Cardiology published the highest number of studies, with 40 articles, whereas Circulation received the highest number of citations (6,266). Key contributors included the United States, Japan, and China, with the United States leading in citation numbers and the H-index. Harvard University and Leiden University emerged as pivotal institutions, and Professors J. Wouter Jukema and Robert P. Giugliano were identified as leading experts. Keyword analysis disclosed five thematic clusters, indicating a shift in research towards new drug combinations and strategies, signaling future research directions.
UNASSIGNED: The last 4 decades have seen a notable rise in publications on lipid-lowering therapies for CHD and hyperlipidemia, with the United States retaining world-leading status. The increase in international collaboration aids the shift towards research into innovative lipid-lowering agents and therapeutic approaches. PCSK9 inhibitors and innovative combination therapies, including antisense oligonucleotides and angiopoietin-like protein 3 inhibitors, provide avenues for future research, intending to maximize the safety and efficacy of treatment approaches.
摘要：
■心血管疾病（CVD）构成了重大的全球健康和经济挑战，动脉粥样硬化是主要原因。在过去的40年里,已经对预防和逆转动脉粥样硬化进行了大量研究，导致降脂药如他汀类药物和贝特类药物的发展。尽管在这一领域有大量的文献和许多治疗指南的制定，尚未对当前的研究格局和趋势进行全面的文献计量分析。本研究旨在通过文献计量分析阐明冠心病（CHD）与高脂血症的降脂治疗研究的进展和里程碑。提供对未来治疗策略方向的见解。
■这项研究检查了1986年至2023年从WebofScience数据库（CoreCollection）检索的出版物。利用VOSviewer等工具，Pajek,和城市空间,我们分析了出版物和引文编号，H指数，国家和机构的捐款，作者身份,期刊来源,和关键词用法，以揭示研究轨迹和重点领域。
■我们对587种出版物的分析显示，研究产出最近激增，特别是2003年后。美国心脏病学杂志发表的研究数量最多，有40篇文章,而Circulation收到的引用次数最多(6,266次)。主要贡献者包括美国，Japan,和中国,美国在引文数量和H指数方面处于领先地位。哈佛大学和莱顿大学成为关键机构，J.WouterJukema教授和RobertP.Giugliano教授被确定为主要专家。关键词分析披露了五个专题组，表明研究转向新的药物组合和策略，预示着未来的研究方向。
在过去的40年中，关于冠心病和高脂血症的降脂疗法的出版物显着增加，美国保持世界领先的地位。国际合作的增加有助于转向研究创新的降脂药和治疗方法。PCSK9抑制剂和创新的联合疗法，包括反义寡核苷酸和血管生成素样蛋白3抑制剂，为未来的研究提供途径，旨在最大限度地提高治疗方法的安全性和有效性。
■这项研究检查了1986年至2023年从WebofScience数据库（CoreCollection）检索的出版物。利用VOSviewer等工具，Pajek,和城市空间,我们分析了出版物和引文编号，H指数，国家和机构的捐款，作者身份,期刊来源,和关键词用法，以揭示研究轨迹和重点领域。
■我们对587种出版物的分析显示，研究产出最近激增，特别是2003年后。美国心脏病学杂志发表的研究数量最多，有40篇文章,而Circulation收到的引用次数最多(6,266次)。主要贡献者包括美国，Japan,和中国,美国在引文数量和H指数方面处于领先地位。哈佛大学和莱顿大学成为关键机构，J.WouterJukema教授和RobertP.Giugliano教授被确定为主要专家。关键词分析披露了五个专题组，表明研究转向新的药物组合和策略，预示着未来的研究方向。
在过去的40年中，关于冠心病和高脂血症的降脂疗法的出版物显着增加，美国保持世界领先的地位。国际合作的增加有助于转向研究创新的降脂药和治疗方法。PCSK9抑制剂和创新的联合疗法，包括反义寡核苷酸和血管生成素样蛋白3抑制剂，为未来的研究提供途径，旨在最大限度地提高治疗方法的安全性和有效性。
